Abiopharma

RepliCel Life Sciences Inc. is developing autologous cell therapies to treat conditions including chronic tendon injuries, pattern baldness and UV-damaged and aging skin. All products are based on RepliCels innovative technology which utilizes cells isolated from a patients healthy hair follicles. RepliCel has also developed a proprietary, next-generation dermal injection device (RCI) designed for highly controllable delivery of dermatological injections. Three phase 1 clinical studies have been completed for RCH-01 for pattern baldness from Androgenic Alopecia, RCT-01 for chronic Achilles tendinosis, and RCS-01 for aging and UV-damaged skin. A phase 2, dose-finding clinical study of RCH-01 for androgenic alopecia has also now been completed. All trials successfully met their primary endpoints and provided significantly positive clinical efficacy data on secondary endpoints. Shiseido Company has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China, and South Korea. They are now funding a pivotal study in Japan. In late 2018, RepliCel signed a license and co-development deal for its skin, tendon and injector technologies with YOFOTO (China) Health for Greater China.

Additional info from OTC:
RepliCel Life Sciences Inc. is developing autologous cell therapies to treat conditions including chronic tendon injuries, pattern baldness and UV-damaged and aging skin. All products are based on RepliCels innovative technology which utilizes cells isolated from a patients healthy hair follicles. RepliCel has also developed a proprietary, next-generation dermal injection device (RCI) designed for highly controllable delivery of dermatological injections. Three phase 1 clinical studies have been completed for RCH-01 for pattern baldness from Androgenic Alopecia, RCT-01 for chronic Achilles tendinosis, and RCS-01 for aging and UV-damaged skin. A phase 2, dose-finding clinical study of RCH-01 for androgenic alopecia has also now been completed. All trials successfully met their primary endpoints and provided significantly positive clinical efficacy data on secondary endpoints. Shiseido Company has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China, and South Korea. They are now funding a pivotal study in Japan. In late 2018, RepliCel signed a license and co-development deal for its skin, tendon and injector technologies with YOFOTO (China) Health for Greater China.